No

Toxoid

Active immunization of infants and children through 5 years of age (between 2 months and the sixth birthday) against diphtheria, tetanus, and pertussis and Haemophilus b disease when indications for immunization with DTP vaccine and HIB vaccine coincide

B

Children with any febrile illness or active infection, known hypersensitivity to Haemophilus b polysaccharide vaccine (thimerosal), children who are immunosuppressed or receiving immunosuppressive therapy; patients >7 years of age, patients with cancer, immunodeficiencies, an acute respiratory infection, or any other active infection; children with a history of neurologic disorders should not receive the pertussis or any component; history of any of the following effects from previous administration of pertussis vaccine precludes further use: fever >103°F (39.4°C), convulsions, focal neurologic signs, screaming episodes, shock, collapse, sleepiness or encephalopathy; known hypersensitivity to diphtheria and tetanus toxoids or pertussis vaccine; do not use DTP for treatment of actual tetanus, diphtheria or whooping cough infections

If adverse reactions occurred with previous doses, immunization should be completed with diphtheria and tetanus toxoid absorbed (pediatric); any febrile illness or active infection is reason for delaying use of Haemophilus b conjugate vaccine

>10%:

Central nervous system: Fever, chills, irritability, restlessness, drowsiness

Local: Erythema, edema, induration, pain and warmth at injection site

1% to 10%:

Dermatologic: Rash

Gastrointestinal: Vomiting, diarrhea, loss of appetite

<1%: Convulsions, screaming episodes, malaise, sleepiness, focal neurological signs, shock, collapse, chills, urticaria, local tenderness, arthralgia, increased risk of Haemophilus b infections in the week after vaccination, rarely allergic or anaphylactic reactions

Decreased effect: Immunosuppressive agents; may interfere with antigen detection tests

Keep in refrigerator, may be frozen (not diluent) without affecting potency; unopened vials are stable for up to 24 hours at <70°C

Promotes active immunity to diphtheria, tetanus, pertussis, and H. influenzae by inducing production of specific antibodies and antitoxins.

The primary immunization for children 2 months to 5 years of age, ideally beginning at the age of 2-3 months or at 6-week check-up. Administer 0.5 mL I.M. on 3 occasions at ~2-month intervals, followed by a fourth 0.5 mL dose at ~15 months of age.

Give only I.M.

A nodule may be palpable at the injection site for a few weeks

Acetaminophen 10-15 mg/kg before and every 4 hours to 12-24 hours may reduce or prevent fever

Shake well before administering

The child's medical record should document that the small risk of past vaccination seizure and the benefits of the pertussis vaccination were discussed with the patient

Injection: Diphtheria toxoid 12.5 Lf units, tetanus toxoid 5 Lf units, and whole-cell pertussis vaccine 4 units, and Haemophilus influenzae type b oligosaccharide 10 mcg per 0.5 mL (5 mL)